Stocks To Buy Now

Blog


Facebook’s Former Head of Advertising Joins NobleCon18 Lineup

Noble Capital Markets has announced that Rob Goldman will be a featured Metaverse panelist at NobleCon18, which feature presentations from 120 public companies on April 20 and 21 at The Guitar Hotel near Miami, FL. Joining Facebook (NASDAQ: FB) in 2012 reporting directly to CEO Mark Zuckerberg, Goldman was charged with growing and monetizing the burgeoning social media platforms (including subsidiaries such as Instagram). During his tenure at Facebook, revenues grew from $5 billion to over $70 billion in a span of seven years. Goldman’s move to Facebook happened when his company, Threadsy, was acquired by the social media giant in a move that many refer to as one of “Mark Zuckerberg’s acqui-hires.” Goldman’s company started out as a way for people to see their social feeds and communication from different networks, like Facebook and Twitter, in one place. But Goldman soon changed the focus towards a paid service that helped brands see which influencers they needed to establish relationships with in order to find new customers on social networks. The change resulted in the development of the social marketing tool Swaylo, which ultimately attracted the attention of Zuckerberg. Mr. Goldman is a graduate of Harvard Business School. Admission to NobleCon is free for all levels of investors from self-directed novices to institutional investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000. To secure a ticket, visit https://nobleconference.com/register/investor-guest Full list of speakers: https://channelchek.com/news-channel/Scheduled_Speakers_NobleCon18 The presenting companies: https://channelchek.com/news-channel/NobleCon18_Presenting_Companies

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 17, 2026

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]

Rotate your device 90° to view site.